Patient characteristics
| Overall | Amsterdam | Bristol | Vienna | |
|---|---|---|---|---|
| Participants, n (n per group*) | 47 (18,14,15) | 22 (8,7,7) | 12 (5,4,3) | 13 (5,4,3) |
| Disease duration in years, mean (min–max) | 8 (1–40) | 6 (1–14) | 11 (1–40) | 10 (1–27) |
| Age in years, mean (min–max) | 56 (29–76) | 58 (30–76) | 52 (29–65) | 57 (35–71) |
| Gender (% female) | 66 | 64 | 75 | 62 |
| Self-perceived remission, n (%) | 24 (51) | 13 (59) | 4 (33) | 7 (54) |
| Past experience with self-perceived remission, n (%) | 37 (79) | 18 (82) | 7 (58) | 12 (92) |
| ACR/EULAR remission, n (%) | 13 (32) | 7 (32) | 1 (20)† | 5 (39) |
| PtGA (mean, min–max) | 2,9 (0–9) | 2,5 (0–8) | 4,5 (0,5–9) | 2,0 (0–5) |
| Disease activity score based on a 28 joint count, mean (SD) | 2,3 (1,6) | 1,8 (1,2) | 3,8 (1,8) † | 2,6 (1,6) |
*Groups included: ACR/EULAR remission group, self-perceived remission group, moderate to high disease activity group.
†7 out of 12 missing data, as not all patients in Bristol had recent joint assessments to enable calculation of their remission status.
PtGA, patient global assessment of disease activity.